PRMT5 and myeloproliferative neoplasm: In fact, the PRMT5 inhibitor C220 displayed efficacy against the disease phenotypes of MPN mouse models, including inhibition of bone marrow fibrosis, and for some parameters of disease, it produced enhanced effects with ruxolitinib in these models.